OSLO, Norway and LONDON, April 7, 2021 /CNW/ — EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Firm”), a scientific stage precision drugs firm using Acoustic Cluster Remedy (ACT®) throughout a number of therapeutic areas, as we speak introduced the appointment of Dominic Moreland as Chief Monetary Officer who shall be primarily based on the London workplace of EXACT-Tx in White Metropolis.
“We’re delighted to welcome Dominic to EXACT Therapeutics AS the place his robust prior expertise in each finance and operations within the biopharmaceutical sector, most not too long ago as VP Finance at Autolus Therapeutic Plc, shall be pivotal in driving ahead our group”, mentioned Dr Rafiq Hasan, CEO of EXACT Therapeutics AS. “Dominic joins EXACT-Tx at an thrilling time as we proceed to develop our presence within the UK and progress our plans for the longer term improvement of ACT®”.
Dominic, a chartered accountant and graduate from the London College of Economics, constructed his profession foundations working in audit at KPMG. He subsequently gained expertise in each finance and operations in a wide range of life sciences firms, together with ICI/Zeneca, Baxter, Genzyme, two impartial companies, Careology and the Whiteley Clinic in addition to Autolus Therapeutics plc. Throughout this time Dominic additionally led the administration buyout of Genzyme’s homecare enterprise to kind Careology Ltd the place he was each founder and CEO. Having efficiently grown the homecare enterprise, Careology was acquired by Medco Well being Options in 2010. At Autolus Therapeutics, Dominic was instrumental within the main each the preparation and execution of the profitable IPO and NASDAQ itemizing in 2018.
Dominic commented: “I’m excited to be becoming a member of EXACT Therapeutics because the workforce continues to develop in London with the continuing scientific improvement of ACT® within the section I ACTIVATE examine. I’m wanting ahead to working with the workforce as we put together for the longer term improvement of this progressive platform know-how.”
EXACT-Tx is a scientific stage Norwegian biotech firm growing a know-how platform for focused therapeutic enhancement – Acoustic Cluster Remedy (ACT®). ACT® sonoporation is a singular strategy to ultrasound-mediated, focused drug enhancement – with the potential to considerably amplify the scientific utility of a variety of therapeutic brokers throughout a mess of indications together with inside oncology (chemotherapy, immunotherapy), infectious illnesses, and neurological circumstances. www.exact-tx.com
For extra info contact:
Dr Rafiq Hasan
CEO EXACT Therapeutics
Richard Hayhurst/Janet Pleasure
Tel +44 7711 821527
SOURCE EXACT THERAPEUTICS AS
View authentic content material: http://www.newswire.ca/en/releases/archive/April2021/07/c0138.html